Applied Therapeutics, Inc. (APLT)
Feb 3, 2026 - APLT was delisted (reason: acquired by Cycle Pharmaceuticals)
0.103
0.00 (0.00%)
Inactive · Last trade price
on Feb 2, 2026
Applied Therapeutics Stock Forecast
APLT's stock price has decreased by -82.44% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Applied Therapeutics stock had an average target of 1.25, with a low estimate of 1.00 and a high estimate of 1.50.
Analyst Consensus: Hold
* Price targets were last updated on Dec 3, 2025.
Analyst Ratings
The average analyst rating for Applied Therapeutics stock from 2 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $2 → $1 | Buy → Hold | Downgrades | $2 → $1 | +870.87% | Dec 3, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $1.5 | Hold | Reiterates | $1.5 | +1,356.31% | May 14, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 23, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $4 → $1.5 | Hold | Maintains | $4 → $1.5 | +1,356.31% | Dec 20, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $13 → $2 | Strong Buy → Hold | Downgrades | $13 → $2 | +1,841.75% | Dec 2, 2024 |
Financial Forecast
Revenue This Year
1.02M
from 455.00K
Increased by 124.18%
Revenue Next Year
1.28M
from 1.02M
Increased by 25.00%
EPS This Year
-0.54
from -0.76
EPS Next Year
-0.44
from -0.54
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1M | 5.3M | ||||
| Avg | 1.0M | 1.3M | ||||
| Low | 980,000 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 130.8% | 414.7% | ||||
| Avg | 124.2% | 25.0% | ||||
| Low | 115.4% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.49 | -0.30 | ||||
| Avg | -0.54 | -0.44 | ||||
| Low | -0.61 | -0.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.